We have joined with three other UK charities to launch an appeal against a NICE (National Institute for Health and Clinical Excellence) decision that could lead to thousands of people with diabetes needlessly losing their sight.
NICE's flawed decision
Diabetes UK, Juvenile Diabetes Research Foundation (JDRF), Macular Disease Society and RNIB are calling for the drug Lucentis to be made available on the NHS to treat the condition diabetic macular oedema (DMO). However, NICE proposes not to recommend it, judging that it is not cost-effective enough.
We feel that RNIB and other key stakeholders have not been able to comment on significant new evidence about the sight saving drug submitted to NICE by the drug's manufacturer.
We want a proper consultation allowing stakeholders to submit their evaluations.
"Patients at risk of losing their sight have a right to expect that a full review of all the available information takes place.
"However, NICE has failed to consult with experts from patient organisations on this new evidence, nor have they sought advice from clinicians who treat people with this condition on a daily basis.
"We strongly believe that some of the assumptions they have made about the cost-effectiveness of the treatment are wrong."
Steve Winyard, RNIB Head of Policy and Campaigns
Steve talks about this on the BBC's In Touch programme
Further information
For further information about this appeal please contact the campaigns team on 020 7391 2123 or campaigns@rnib.org.uk